Ett svagt kvartal Bolagets nettoomsättning uppgick till 1,0 mkr (3,6 mkr) och rörelseresultatet blev...
Ultimovacs’ Q322 results highlighted an eventful period for the development of the company’s lead ca...
Omsättning något över våra estimat Omsättningen uppgick till EUR 12,9m vs våra estimat om EUR 12,3, ...
Q3 i korthet Nettoresultatet var -23 mkr (-36) jämfört med vår förväntan om -56 mkr.
Redey is happy to see Image Systems delivering very strong Q3 numbers, with earnings and margins at ...
EBIT SEK 37m vs. ABGSCe SEK 41m Disappointing guidance for Q4’22 Conference call at 09.
IFreja’s Q3 report confirmed our positive views and our concerns.
Redeye leaves a short comment on today’s news that Xbrane and STADA have secured EU approval for Xim...
Media and Games Invest’s (MGI’s) recent EGM confirmed that the group can now proceed with its reloca...
Redeye provides a first comment on the back of Modelon's Q3 report.
Adj. EBIT SEK 130m (+65% vs. ABGSCe 79m) Still looking to divest Russian business 1.
Sammantaget var kvartalet positivt med ett förväntat utfall.
Redeye states that the Q3 report was more or less in line with estimates, albeit somewhat on the low...
Monivent har en pågående företrädesemission om cirka 14,8 MSEK och en riktad emission om cirka 1,6 M...
Redeye leaves its fair value range unchanged on the back of this Q3 report, which was in line with o...
Redeye updates its estimates and base case following Freemelt’s Q3 report, which came in slightly be...
Redeye embraces the strong gross margin of 84% vs REe of 80% in the quarter, and we judge the slight...
Redeye updates its estimates following Surgical Science’s Q3 2022 report, which we judge featured so...
Redeye comments on Ultimovacs’ Q3 2022 report, as the company’s lead candidate is approaching its pr...
Relais' Q3 results were in line with our expectation and above the low-quality Refinitiv consensus.
